Genentech/NNP Inc./NNP said/VBD third-quarter/JJ profit/NN more/RBR than/IN doubled/VBD to/TO $/$ #.#/CD million/CD ,/, or/CC #/CD cents/NNS a/DT share/NN ,/, from/IN a/DT depressed/JJ #/CD third-quarter/JJ performance/NN of/IN $/$ #.#/CD million/CD ,/, or/CC six/CD cents/NNS a/DT share/NN ./.
Revenue/NN rose/VBD #/CD %/NN to/TO $/$ #/CD million/CD from/IN $/$ #.#/CD million/CD ./.
Net/JJ product/NN sales/NNS accounted/VBD for/IN $/$ #/CD million/CD ,/, up/RB from/IN $/$ #.#/CD million/CD a/DT year/NN earlier/RB ./.
Sales/NNS of/IN the/DT heart/NN drug/NN TPA/NNP were/VBD $/$ #.#/CD million/CD ,/, better/JJR than/IN last/JJ year/NN 's/POS depressed/JJ third/JJ period/NN when/WRB the/DT company/NN sold/VBD just/RB $/$ #.#/CD million/CD of/IN the/DT drug/NN ./.
But/CC TPA/NNP sales/NNS fell/VBD below/IN levels/NNS for/IN this/DT year/NN 's/POS first/JJ and/CC second/JJ quarter/NN sales/NNS of/IN $/$ #/CD million/CD ,/, cooling/VBG investors/NNS ./.
Genentech/NNP stock/NN fell/VBD #.#/CD cents/NNS in/IN trading/NN yesterday/NN on/IN the/DT New/NNP York/NNP Stock/NNP Exchange/NNP to/TO $/$ #.#/CD ./.
In/IN the/DT nine/CD months/NNS ,/, net/JJ income/NN slid/VBD #/CD %/NN to/TO $/$ #.#/CD million/CD ,/, or/CC #/CD cents/NNS a/DT share/NN ,/, from/IN $/$ #/CD million/CD ,/, or/CC #/CD cents/NNS a/DT share/NN ./.
Revenues/NNS climbed/VBD #/CD %/NN to/TO $/$ #/CD million/CD from/IN $/$ #.#/CD million/CD ./.
``/`` We/PRP continue/VBP to/TO be/VB on/IN target/NN for/IN .../: increasing/VBG TPA/NNP sales/NNS #/CD %/NN to/TO #/CD %/NN this/DT year/NN ,/, ''/'' said/VBD founder/NN and/CC Chief/NNP Executive/NNP Officer/NNP Robert/NNP Swanson/NNP ./.
But/CC some/DT analysts/NNS remain/VBP sour/JJ on/IN the/DT company/NN ./.
``/`` TPA/NNP sales/NNS are/VBP down/RB quarter/NN to/TO quarter/NN ./.
Expenses/NNS are/VBP flat/JJ and/CC that/DT 's/VBZ a/DT good/JJ sign/NN ./.
There/EX 's/VBZ contract/NN revenue/NN from/IN -LCB-/-LRB- limited/JJ research/NN and/CC development/NN -RCB-/-RRB- partnerships/NNS ./.
But/CC I/PRP still/RB think/VBP the/DT fundamentals/NNS are/VBP poor/JJ ,/, ''/'' said/VBD Denise/NNP Gilbert/NNP ,/, an/DT analyst/NN with/IN Montgomery/NNP Securities/NNPS in/IN San/NNP Francisco/NNP ./.
Genentech/NNP faces/VBZ competition/NN in/IN the/DT cardiac-drug/JJ market/NN from/IN SmithKline/NNP Beecham/NNP PLC/NNP 's/POS heart/NN drug/NN Eminase/NNP ,/, expected/VBN to/TO receive/VB market/NN approval/NN shortly/RB ./.
And/CC Genentech/NNP is/VBZ n't/RB likely/JJ to/TO have/VB any/DT new/JJ products/NNS ready/JJ for/IN market/NN until/IN at/IN least/JJS #/CD ,/, Ms./NNP Gilbert/NNP added/VBD ./.
``/`` The/DT company/NN 's/POS stock/NN is/VBZ trading/VBG at/IN #/CD times/NNS next/JJ year/NN 's/POS numbers/NNS ,/, and/CC that/DT 's/VBZ too/RB much/JJ ,/, ''/'' she/PRP said/VBD ./.
On/IN the/DT plus/JJ side/NN ,/, Genentech/NN is/VBZ benefiting/VBG from/IN a/DT lower/JJR tax/NN rate/NN due/JJ to/TO its/PRP$ research/NN outlays/NNS ,/, giving/VBG a/DT boost/NN to/TO earnings/NNS ,/, she/PRP said/VBD ./.
